Ilkka Oyj                               Stock Exchange Release 26 March 2026, at 07:00 p.m. EET Ilkka Oyj: Acquisition of own shares on 26 March 2026Date 26 March 2026  Exchange transaction Buy  Share trading code ILKKA2  Amount, shares 2,100  Average price/share (EUR) 4.2390  Total cost (EUR) 8,901.90  After the acquisitions Ilkka Oyj holds a total of  138,561 treasury shares (ILKKA2). On behalf of Ilkka Oyj Danske Bank A/S, Finland Branch Antti Väliaho                         Jonathan Nyberg For more information, please contact:Olli Pirhonen, CEO, Ilkka Oyjolli.pirhonen@ilkka.com DISTRIBUTIONNasdaq HelsinkiMain mediawww.ilkka.com Ilkka Oyj in briefIlkka is a marketing and technology company that offers professional, data and technology services in digital marketing and communications. The core of Ilkka’s business...

Regulated information – March 26, 2026 – 18:00 CET Campine reports an exceptional financial performance for 2025, marked by extraordinary market conditions. Consolidated revenue doubled to €766 million, while operating cash flow (EBITDA) reached a new record of €89 million, more than doubling compared to the previous year. The exceptional circumstances in the global antimony market enabled Campine to significantly expand its exports of antimony trioxide, strengthening its position as the world’s leading producer in this market. In addition, higher antimony metal prices — the key pricing basis for Campine’s products — drove a sharp increase in revenue. At the same time, Campine continued to strengthen its circular metals activities through a strategic acquisition of Ecobat’s European battery recycling operations, adding two smelters in...

Press release Communiqué de presse PersberichtRegulated Syensqo successfully completes its LTI Share Buyback Program Brussels, Belgium – March 26, 2026 18:00 CET  Syensqo is pleased to announce the successful completion of its 2026 LTI Share Buyback Program. The program, announced on March 23,  2026, was concluded on March 25, 2026.  This program, authorized by the Syensqo Board of Directors, was designed to cover current and future obligations under Syensqo’s Long Term Incentive Plans for its employees. Syensqo shares were purchased through intra-group acquisitions from Syensqo Stock Option Management SA (SSOM) and acquisitions on the regulated markets. Weekly updateIn accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code of Companies and Associations, Syensqo SA (“Syensqo” or the “Company”)...

Press releaseRegulated information Syensqo notifies bondholders of the Redemption Price for its €500 million senior bonds Brussels, March 26, 2026 – 6.15 pm CET Following the publication by the Issuer on 27 February 2026 of a notice announcing Syensqo’s decision to redeem all of the outstanding 2.750 per cent. Fixed Rate Bonds due December 2, 2027 (the “Bonds”) on Tuesday 31 March 2026, the company today announced the total redemption price.  The Bonds will be redeemed at an aggregate redemption price equal to the principal amount of 500,000,000.00 € plus accrued interest of 4,482,900.00 €. In accordance with the Conditions of the Bonds, KBC Bank NV, in its capacity as Calculation Agent, has today determined the Reference Rate for the redemption (3.062%). KBC Bank NV  has also computed the Make-whole Amount (100,000.00...

Company announcement – inside information No. 20/2026                                                  26 March 2026 Netcompany raises full-year margin guidance for 2026 Netcompany’s continued focus on delivery excellence and implementation, supported by the ongoing embedding of AI capabilities into our methodology has led to increased expectation for adjusted EBITDA margin for the full-year 2026. “As a leading European provider of complex IT solutions in regulated environments across public and private sectors, we constantly strive to become better at what we do. The continuous investment over recent years in AI-embedded platforms and products and responsible AI executable methodology has positioned Netcompany as a European leader in delivering and/or renovating highly complex high-quality systems on time and within budget with reduced...

CHICAGO, March 26, 2026 (GLOBE NEWSWIRE) — XA Investments LLC (XAI), a Chicago-based alternative investment management and consulting firm, announced that Lauren Michalak has joined the firm as a managing director and head of product development and strategy, leading efforts in those areas for the firm’s proprietary closed-end funds. She will also serve the firm’s interval fund consulting clients and research clients. “Lauren has spent two decades operating at the intersection of product innovation, strategy, and enterprise execution. She has led every stage of the product development lifecycle across multiple fund structures, raised over $15 billion of new capital, and driven complex, cross-functional initiatives—bringing the discipline needed to turn ideas into market-ready offerings. We’re excited for her to help shape the next...

Sanoma Corporation, Stock exchange release, 26 March 2026 at 18:30 EET SANOMA CORPORATION: ACQUISITION OF OWN SHARES 26 March 2026 Nasdaq Helsinki Ltd:Date 26 March 2026  Exchange transaction Buy  Share class SANOMA  Amount 22,000  Average price/share, EUR 9.0884  Highest price/share, EUR 9.1100  Lowest price/share, EUR 9.0200  Total cost, EUR 199,944.80       The share buybacks are executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052. The company holds a total of 1,075,392 of its own shares (SANOMA) including the shares acquired on 26 March 2026. Detailed information concerning the acquisition is attached to this stock exchange release. On behalf of Sanoma Corporation Skandinaviska Enskilda Banken...

March 26, 2026 MONTHLY DISCLOSURE OF THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Articles L. 233-8 II of the Commercial Code and 223-16 of the General Regulation of the AMFDate   Shares   Voting rightsTheoretical* Exercisable**28 February 2026 43,203,225 49,276,265 49,093,732*This number is calculated on the basis of all the shares to which voting rights are attached, including shares which voting rights have been suspended, in accordance with Article 223-11 of the AMF general regulation related to the calculation of the crossing of thresholds with regard to the number of voting rights. **For information purposes, this number excludes the shares which voting rights have been suspended. The information is also available in the « Regulated Information » section of the Ipsos website: https://www.ipsos.com/en/regulated-informations/en....

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue GrowthTevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue GrowthPotential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen’s position in oncology, rare diseases, and medical devices Target CRO operates across 20+ countries, providing global clinical development capabilitiesWARREN, N.J., March 26, 2026 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it is in advanced-stage evaluation of a niche contract research organization (CRO) with multi-country operations and established relationships across oncology, rare diseases, and medical devices. If...

Strasbourg, France, March 26, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced a 30-minute oral presentation on TG4050, the Company’s Individualized Neoantigen Therapeutic Vaccine (INTV) at the World Vaccine Congress (WVC), taking place from March 31 to April 2, 2026, in Washington, D.C., USA. The presentation will be held on April 1st. The presentation will highlight findings of the Phase 1 part of the ongoing Phase 1/2 trial in head and neck cancer. Transgene will also discuss the potential of INTVs to reshape early-stage cancer treatment. “We are delighted to share our positive data on our lead asset TG4050 with the scientific community”, said Katell Bidet Huang, PhD, Head of Translational Medicine at Transgene.“TG4050...